EGFR and non-small cell lung carcinoma: Importantly, our current study does not rule out the potential involvement of additional resistance mechanisms to EGFR-TKIs, underscoring the necessity of comprehensive investigations to fully elucidate the molecular determinants of treatment response and resistance in EGFR-mutant NSCLC.